More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$6.53B
EPS
-2.1
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
-0.318624
Previous close
$99.24
Today's open
$98.51
Day's range
$95.05 - $100.77
52 week range
$25.23 - $115.52
show more
CEO
Lawrence Klein
Employees
68
Headquarters
Menlo Park, CA
Exchange
NASDAQ Global Market
Shares outstanding
67822359
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Oruka Therapeutics, Inc. (ORKA) Presents at UBS Global Biopharma Conference 2026 Transcript
Oruka Therapeutics, Inc. (ORKA) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • a day ago

Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A
GlobeNewsWire • Nov 9, 2026

Oruka Therapeutics to Participate in Multiple Upcoming Conferences
MENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its participation and presentation at multiple upcoming conferences: Guggenheim 3 rd Annual Healthcare Innovation Conference Date: November 10, 2026 Presentation Time: 11:00 AM EST Stifel 2026 Healthcare Conference Date: November 11, 2026 Presentation Time: 4:00 PM EST UBS Global Biopharma Conference Date: November 17, 2026 Presentation Time: 4:00 PM GMT Jefferies Global Healthcare Conference Date: November 18, 2026 Presentation Time: 4:30 PM GMT Webcasts and replays of Oruka's presentations will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.
GlobeNewsWire • Nov 3, 2026

Oruka's ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study
Oruka Therapeutics NASDAQ: ORKA reported interim week 16 results from EVERLAST-B, a Phase IIb dose-ranging study of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The company said its 600-milligram regimen achieved complete skin clearance, measured by PASI 100, in 61% of participants at week 16, while 86% achieved PASI 90.
MarketBeat • Oct 27, 2026

Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial
Oruka Therapeutics Inc. (NASDAQ:ORKA) on Monday reported positive Week 16 results from its EVERLAST-B Phase 2b clinical trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis.
Benzinga • Oct 26, 2026

Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript
Seeking Alpha • Oct 26, 2026

Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ORKA-001 on track to advance into Phase 3 trials in 1H 2027 52-week EVERLAST-A results on track for December 2026 ORKA-002 16-week results from ORCA-SURGE Phase 2 in psoriasis on track for 1Q 2027 Management to host conference call today at 8:00 a.m. ET MENLO PARK, Calif.
GlobeNewsWire • Oct 26, 2026

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.
GlobeNewsWire • Oct 25, 2026

Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far End
Oruka Therapeutics is positioned as a leader in ultra-long-acting injectable treatments for psoriasis, with ORKA-001 showing class-leading efficacy. ORKA-001's PASI 100 and PASI 90 rates at Week 28 reinforce its durability, while a replicated response in the crossover cohort strengthens confidence in trial results. ORKA's $1.1B cash balance, exclusive Hypercon technology license, and pipeline breadth provide funding through BLA and strategic flexibility amid rising R&D spend.
Seeking Alpha • Oct 18, 2026

ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.
Zacks Investment Research • Sep 24, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Oruka Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.